Impact of Rapid Diagnostics using a FilmArray Test and Early Targeted Treatment with Ceftazidime-Avibactam for Management of Severe Infections: A Comparative Study Against Standard Care
- Conditions
- Health Condition 1: B962- Escherichia coli [E. coli ] as thecause of diseases classified elsewhereHealth Condition 2: B961- Klebsiella pneumoniae [K. pneumoniae] as the cause of diseases classified elsewhereHealth Condition 3: B968- Other specified bacterial agents as the cause of diseases classified elsewhereHealth Condition 4: B965- Pseudomonas (aeruginosa) (mallei)(pseudomallei) as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2024/04/066197
- Lead Sponsor
- ADVANCE ID
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
a) At risk of bloodstream infections, hospital-acquired pneumonia or ventilator-associated pneumonia due to Pseudomonas aeruginosa or carbapenemase producing Enterobacterales; OR,
b) whose blood culture bottles growing Gram negative bacilli; OR,
c) who are suspected to have hospital-acquired pneumonia or ventilator-associated pneumonia and whose respiratory samples show Gram negative bacteria on Gram stain
a) Refractory shock or comorbid condition such that patient not expected to survive more than 48 hours; OR,
b) where the bloodstream infection is thought to be related to a vascular catheter and the catheter is unable to be removed; OR,
c) treatment is not with the intent to cure the infection; OR,
d) patients previously randomised in this trial within the last 60 days.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method